| Document |
Document Title |
|
WO/2020/121171A1 |
Systems and methods for producing dicyclopentadiene via thermal dimerization of cyclopentadiene. The feed stream comprising cyclopentadiene is flowed through four shell and tube heat exchangers in series. Each of the shell and tube heat ...
|
|
WO/2020/120794A2 |
The present invention relates to a organic light emitting device comprising a cathode, an anode, a light emitting layer, at least one first electron transport layer and at least one second electron transport layer, wherein the light emit...
|
|
WO/2020/112357A1 |
Provided herein are compounds of Formula (I), including methods of making the same. The disclosed compounds are succinate dehydrogenase inhibitors and can be useful in, e.g., inhibiting or preventing fungal growth.
|
|
WO/2020/105711A1 |
This indene composition has an indene content of 80 to 99.5 mass%. With respect to components other than indene, the content ratio of a C9 or C10 hydrocarbon compound having a 5-member or 6-member condensed ring structure is 90 mass% or ...
|
|
WO/2020/094953A1 |
The invention relates to the use of at least one cyclophane in a plastic scintillator, as an agent for discriminating between neutrons and gamma rays, as a substitute for the fluorophores which are used in plastic scintillators or as a c...
|
|
WO/2020/091968A1 |
A catalyst comprising a microporous crystalline metallosilicate having a Constraint Index of 12, or 10, or 8, or 6 or less, a binder, a Group 1 alkali metal or a compound thereof and/or a Group 2 alkaline earth metal or a compound thereo...
|
|
WO/2020/091969A1 |
A catalyst comprising a microporous crystalline aluminosilicate having a Constraint Index less than or equal to 12, a Group 1 alkali metal or a compound thereof and/or a Group 2 alkaline earth metal or a compound thereof, a Group 10 meta...
|
|
WO/2020/086898A1 |
This invention employs columns and methods to apply external and internal standards and compounds. Analytical standard or compounds are adsorbed to a solid phase extraction media and are stored indefinitely. The standards or compounds re...
|
|
WO/2020/062453A1 |
Disclosed are applications of a tyrosinase inhibitor in a facial cream, a facial cleanser, or a whitening lotion. The present invention discovers that β-santalene, epi-β-santalene, a Teucrium viscidum enone, a Teucrium viscidum alkenon...
|
|
WO/2020/054679A1 |
This reaction device (100) for reacting a liquid-phase reactant and a gas-phase reactant converted into fine bubbles comprises: a porous body (10) that includes a plurality of flow paths and in which the flow paths are separated by porou...
|
|
WO/2020/031935A1 |
Provided are a curable resin mixture having excellent heat resistance and electrical characteristics and a curable resin composition thereof. This curable resin mixture has at least one of the cyclopentadiene structures represented by fo...
|
|
WO/2019/075453A9 |
Provided is a method of inhibiting protein kinase C zeta/protein kinase M zeta, including contacting a sample containing an isoform of protein kinase C zeta with a compound of formula: referred to as 1-naphthol-3,6,8-trisulphonic acid, o...
|
|
WO/2020/016902A1 |
The present invention provides an improved and economical process for selective hydrogenation of cyclic di-olefins to their corresponding cyclic mono-olefins, essentially in presence of sonicated S1-modified Raney-Nickel as a highly acti...
|
|
WO/2020/018253A1 |
In a process for separating a dimethylbiphenyl compound from a mixture thereof with a (methylcyclohexyl)toluene compound, the mixture is cooled to a temperature less than the melting point of the dimethylbiphenyl compound but above the t...
|
|
WO/2020/010494A1 |
A fused cycloalkane fuel, a heterogeneous photocatalytic preparation method thereof, and a use of a photocatalyst in improving target product selectivity. The fused cycloalkane fuel has a structure shown in formula (I), wherein n = 1 or ...
|
|
WO/2020/005938A1 |
A method for preventing or treating a tissue injury and/or promoting tissue repair in a subject in need thereof, includes administering to the subject a therapeutically effective amount of an ADH inhibitor, AKR inhibitor, SCoR inhibitor,...
|
|
WO/2020/002338A1 |
A process for the continuous production of a reaction product of a diazo‐compound and a substrate in a multi‐stage flow reactor is disclosed.
|
|
WO/2019/234524A1 |
Systems and methods for producing dicyclopentadiene from cyclopentadiene using reactive jet mixing are disclosed. A C5 hydrocarbon mixture that comprises cyclopentadiene (C5H6) is injected as a jet stream into C5 hydrocarbon liquid in a ...
|
|
WO/2019/231871A1 |
Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed h...
|
|
WO/2019/231870A1 |
Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed h...
|
|
WO/2019/226808A1 |
The present invention features novel peripherally-restricted isoguvacine analogs with reduced blood brain barrier permeability and methods of use thereof for reducing tactile dysfunction, social impairment, and anxiety in a subject diagn...
|
|
WO/2019/212325A1 |
The present invention provides a novel compound and an organic light emitting diode using same.
|
|
WO/2019/207246A1 |
The present invention relates to a method for olefin metathesis, which comprises placing in contact: - at least one olefin, - at least one metathesis catalyst selected from the ruthenium alkylidene complexes comprising two imidazoline-2-...
|
|
WO/2019/208281A1 |
A method for producing indene, which comprises a dehydrogenation step wherein a starting material gas containing indane and molecular hydrogen is brought into contact with a dehydrogenation catalyst, thereby obtaining a reaction product ...
|
|
WO/2019/203430A1 |
The present invention relates to a novel compound and an organic electroluminescent device comprising same. As the compound according to the present invention is used for an organic material layer of an organic electroluminescent device,...
|
|
WO/2019/196780A1 |
The present invention relates to the field of pharmaceutical chemistry. Disclosed are a novel indoleamine-2,3-dioxygenase (IDO) inhibitor, a preparation method therefor, and a use thereof. The IDO inhibitor in the present invention has a...
|
|
WO/2019/191830A1 |
The present application relates generally to the treatment of integumentary wounds (including chronic and acute wounds involving both cutaneous and mucous membranes), and in particular to topical formulations and instillates comprising o...
|
|
WO/2019/189037A1 |
Provided is a fused-ring compound which exhibits excellent charge transport capacity. This fused-ring compound is represented by formula (1) having a specific structure.
|
|
WO/2019/182744A1 |
A process for endothermic dehydrogenation including contacting a catalyst material in a moving bed reactor having at least one reaction zone, the moving bed reactor comprising a heat exchanger containing a heating medium, wherein the cat...
|
|
WO/2019/176248A1 |
This method for producing indene is provided with a dehydrogenation step in which a raw material composition containing indane is brought into contact with a dehydrogenation catalyst to obtain a reaction product containing indene, wherei...
|
|
WO/2019/176247A1 |
This method for producing indane is provided with a dehydrogenation step in which a raw material composition containing tetrahydroindene is brought into contact with a dehydrogenation catalyst under a temperature condition of 150-300°C ...
|
|
WO/2019/169270A1 |
This disclosure relates to compositions and methods for treating cancer. Specifically, this disclosure relates to bexarotene derivatives, methods for treating cancer, autoimmune disorders, and/or skin dermatitis, and/or methods for incre...
|
|
WO/2019/166270A1 |
The invention relates to an organic electronic device comprising at least one electron transport, electron injection or electron generation layer comprising a compound of Formula (I) wherein all positions which are not linked to a -(A)a-...
|
|
WO/2019/169082A1 |
Disclosed are methods for increasing glucagon secretion in response to exogenous insulin-induced hypoglycemia in patients with type l or type 2 diabetes. Also disclosed are methods of increasing glucagon secretion, and thus preventing or...
|
|
WO/2019/169099A1 |
Processes and apparatus for isomerizing hydrocarbons are provided. The process comprises providing a feed stream comprising C5, C6 and C7+ hydrocarbons. The feed stream is separated to produce a first stream rich in C5 and C6 hydrocarbon...
|
|
WO/2019/165350A1 |
The present invention discloses processes for producing normal alpha olefins, such as 1-hexene, 1-octene, 1-decene, and 1-dodecene in a multistep synthesis scheme from another normal alpha olefin. Also disclosed are reactions for convert...
|
|
WO/2019/153954A1 |
Disclosed are a multi-substituted benzene compound having biological activity, a preparation method therefor, and an application thereof. The compound of the present invention has good biological activity and the activity of inhibiting t...
|
|
WO/2019/157195A1 |
The present invention relates to using monoterpene or sesquiterpene to permeabilize the blood brain barrier.
|
|
WO/2019/144805A1 |
Provided are a substituted phenylethylamine compound as a μ opioid receptor agonist, a pharmaceutical composition comprising same, a preparation method therefor and the use of same for preventing and/or treating diseases associated with...
|
|
WO/2019/141095A1 |
A compound represented by formula (I), a pharmaceutical composition, a pharmaceutical formulation and use of the compound in the preparation of a medicament for preventing or treating diseases associated with IDO activity or IDO mediated...
|
|
WO/2019/143495A1 |
Processes are described for separating 3,4'- and 4,4' -dimethylbiphenyl from a mixture comprising at least 3,3'-, 3,4'- and 4,4' -dimethylbiphenyl. In the processes, the mixture is cooled to produce a crystallization product comprising a...
|
|
WO/2019/127921A1 |
The present invention relates to a compound for a polypeptide liquid-phase synthesis carrier, a preparation method therefor and use thereof. Specifically, disclosed is a cyclic ketone compound as a polypeptide liquid-phase carrier, havin...
|
|
WO/2019/127919A1 |
The present invention relates to a carrier compound for liquid phase synthesis of a polypeptide, a preparation method therefor and use thereof, and specifically discloses a fused ring compound which can be used as a liquid phase carrier ...
|
|
WO/2019/132210A1 |
A method for preparing cyclododecene and a synthesis device therefor, of the present invention, remarkably increase the conversion ratio of cyclododecatriene and selectivity of cyclododecene, can minimize the costs required for equipment...
|
|
WO/2019/110299A1 |
Proposed is a process for producing rotundone from α-guaiene, in particular by oxidation of the C(3) position, wherein the α-guaiene is produced from a precursor by a sesquiterpene synthase. The sesquiterpene synthase is produced in a ...
|
|
WO/2019/108943A1 |
The present disclosure provides a benzene fused heterocyclic compound of Formula (I): wherein (A) is a single or double bond; n is 0 or 1; X is -CH2-, O, NR1, or S; A is -C(Ra1)(Ra2)(Ra3) or -N(Ra1)(Ra2), wherein Ra1, Ra2 and Ra3 are ind...
|
|
WO/2019/101813A1 |
The various aspects presented herein relate to the perfumery industry. More particularly, the various aspects presented herein relate to malodor counteracting compositions and/or ingredients, methods for counteracting malodors, as well a...
|
|
WO/2019/101926A1 |
A method comprising catalysis of the conversion of (+)-cis-isopulegone to (R)-(+)-pulegone using a ketosteroid isomerase is disclosed. A mutated ketosteroid isomerase having (+)-cis-isopulegone to (R)-(+)-pulegone isomerase activity is a...
|
|
WO/2019/095052A1 |
The present application relates to methods and uses of CB2 target agent local anaesthetics such as beta-caryophyllene for treatment of interstitial cystitis in a subject, optionally together with the administration or use of an additiona...
|
|
WO/2019/086400A1 |
The invention relates to novel organic semiconducting compounds containing a polycydic unit, to methods for their preparation and educts or intermediates used therein, to compositions, polymer blends and formulations containing them, to ...
|
